Effect of dapagliflozin on periprocedural MI and contrast induced nephropathy: a randomized, double blind control trial

ational Science, Research and Innovation Fund (NSRF)0 个研究点目标入组 292 人开始时间: 2023年1月9日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1.Adult (age 18-75 years old) undergoing elective CAG with possible PCI or elective staged PCI
•2.Diagnosed with chronic coronary syndrome or stable acute coronary syndrome (including unstable angina, non-ST segment elevation myocardial infarction, defined as normal or stable elevated or falling high sensitivity troponin before procedure)
•3.Estimated glomerular filtration rate more than 30 mL/min/1.73m2 (CKD-EPI formula)

•1.Decline for study participation or not provide informed consent
•2.Blood sugar at screening morethan 300 mg/dL
•3.Rise in serum creatinine of more than 50 percentage from the baseline value or presumed to have occurred within 7 days.
•4.History of allergy to any SGLT2 inhibitor
•5.Past or current treatment with any SGLT2 inhibitor
•6.History of type 1 diabetes mellitus
•7.Current use of insulin
•8.Previous history of diabetic ketoacidosis
•9.Current treatment with loop diuretic
•10.History of any genital infection
•11.History of urinary tract infection within 3 months
•12.Currently receiving long term (>30 consecutive days) treatment with an oral steroid, immunosuppressive drug
•13.Pregnant woman or during lactation period
•14.Patients whom their comorbidities, judged by study researcher, may limit the study participation

发起方

ational Science, Research and Innovation Fund (NSRF)